Procyclidine (Kemadrin) for EPS and Parkinsonism.

Procyclidine (Kemadrin) is an anticholinergic drug that is used in the treatment of:

  • Parkinsonism, including:

    • postencephalitic,

    • arteriosclerotic, and

    • idiopathic types.

  • Extrapyramidal side effects induced by phenothiazines such as:

    • Dystonia,

    • Dyskinesia,

    • Akathisia, and

    • Parkinsonism.

Procyclidine dose in Adults

Procyclidine dose in the treatment of Parkinson disease:

  • 2.5 mg orally thrice daily after meals.
  • After each meal, the amount is progressively increased to 5 mg, and if necessary, 5 mg is also given at bedtime.
  • The bedtime dose may be omitted in some patients who are intolerant.

Conversion from alternative therapy:

  • Give a lesser dose, 2.5 mg three times per day, and gradually increase it based on the response and side effects.

Extrapyramidal side effects:

  • 2.5 mg three times a day orally after meals.
  • The dose is increased in increments of 2.5 mg daily (until improvement is noted) to the usual dose of 10 - 20 mg daily.

Procyclidine dose in Children

Pediatric patients have not yet been studied for safety and effectiveness.

Pregnancy Risk Category: C

  • Its use in pregnancy is not well documented.

Use of procyclidine while breastfeeding

  • It is unknown if the drug will be excreted into breastmilk.

Procyclidine dose in Kidney Disease:

It should be used with caution in renal impairment. However, the manufacturer has not recommended any adjustment in the dose in patients with renal disease.

Procyclidine dose in Liver Disease:

You should use caution if you have liver disease. The manufacturer has not advised any adjustments in the dose for patients with liver disease

Procyclidine side effects:

  • Central Nervous System:

    • Dizziness
  • Dermatologic:

    • Skin Rash
  • Gastrointestinal:

    • Constipation
    • Epigastric Distress
    • Nausea
    • Vomiting
    • Xerostomia
  • Hypersensitivity:

    • Hypersensitivity Reaction
  • Neuromuscular & Skeletal:

    • Weakness
  • Ophthalmic:

    • Blurred Vision
    • Mydriasis

Contraindication to Procyclidine (Kemadrin) Include:

  • Angle-closure Glaucoma

Warnings and precautions

  • Hyperthermia/ anhidrosis:

    • Anhidrosis and hyperthermia are side effects of anticholinergic medications that can sometimes be severe, especially during hot weather.
    • In such cases, treatment must be stopped.
    • Hyperthermia is a serious condition that can affect the elderly, CNS patients, and people who have been exposed to hot environments for a long time.
  • CNS effects

    • Use of procyclidine may cause confusion, restlessness and hallucinations.
    • This is more evident in patients with neurological disorders or older people who are taking higher doses.
    • CNS depression may also be caused by it. It should be used with caution by patients who are required to remain alert for mental tasks.
    • A physician should be notified if there are any neuropsychiatric symptoms.
  • Cardiovascular disease

    • Patients suffering from cardiac disease (tachycardias, arrhythmias, hypertension or hypotension) should be cautious.
  • Obstructive GI:

    • Patients suffering from obstructive gastropathy should be cautious.
  • Hepatic impairment

    • Patients with hepatic impairment need to be cautious.
  • Prostatic hyperplasia/Urinary stricture:

    • It is possible to have urinary retention, especially among the elderly, people with BPH, or those who have had a history urinary stricture, or those with a history urinary retention.
  • Renal impairment

    • It should be used with caution by patients with impaired renal function.

Procyclidine (United States: Not available): Drug Interaction

Risk Factor C (Monitor therapy)

Acetylcholinesterase Inhibitors

May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.

Amantadine

May enhance the anticholinergic effect of Anticholinergic Agents.

Anticholinergic Agents

May enhance the adverse/toxic effect of other Anticholinergic Agents.

Botulinum Toxin-Containing Products

May enhance the anticholinergic effect of Anticholinergic Agents.

Cannabinoid-Containing Products

Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Exceptions: Cannabidiol.

Chloral Betaine

May enhance the adverse/toxic effect of Anticholinergic Agents.

Gastrointestinal Agents (Prokinetic)

Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).

Glucagon

Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased.

Itopride

Anticholinergic Agents may diminish the therapeutic effect of Itopride.

Mianserin

May enhance the anticholinergic effect of Anticholinergic Agents.

Mirabegron

Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron.

Nitroglycerin

Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption.

Opioid Agonists

Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.

Ramosetron

Anticholinergic Agents may enhance the constipating effect of Ramosetron.

Thiazide and Thiazide-Like Diuretics

Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics.

Topiramate

Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate.

Risk Factor D (Consider therapy modification)

Pramlintide

May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.

Secretin

Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.

Risk Factor X (Avoid combination)

Aclidinium

May enhance the anticholinergic effect of Anticholinergic Agents.

Cimetropium

Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium.

Eluxadoline

Anticholinergic Agents may enhance the constipating effect of Eluxadoline.

Glycopyrrolate (Oral Inhalation)

Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation).

Glycopyrronium (Topical)

May enhance the anticholinergic effect of Anticholinergic Agents.

Ipratropium (Oral Inhalation)

May enhance the anticholinergic effect of Anticholinergic Agents.

Levosulpiride

Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride.

Oxatomide

May enhance the anticholinergic effect of Anticholinergic Agents.

Potassium Chloride

Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.

Potassium Citrate

Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.

Revefenacin

Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin.

Tiotropium

Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium.

Umeclidinium

May enhance the anticholinergic effect of Anticholinergic Agents.

Monitor:

  • Extrapyramidal symptoms, Parkinson's disease.
  • Pulse
  • Anticholinergic effects such as CNS, bladder and bowel function

How to administer Procyclidine (Kemadrin)?

It should be taken after a meal to minimize the anticholinergic side effects and maximize the gastrointestinal tolerance.

Mechanism of action of Procyclidine (Kemadrin):

  • It is an anticholinergic drug, which acts by blocking the cerebral acetylcholine receptors.
  • It reduces salivation and acts on the smooth muscles to prevent spasm. It can also cause mydriasis.

The onset of action is 45 - 60 minutes.

The duration of action lasts for up to 12 hours.

Distribution: V : 1 L/kg.

Metabolism: It is metabolized by hydroxylation of the alicyclic groups.

Bioavailability is about 75%

Half-life elimination: about 12.6 hours

Time to reach peak plasma concentration is about 1.1 hours

Excretion: is via Urine (predominantly as metabolites)

International Brands of Procyclidine:

  • PDP-Procyclidine
  • Akinetic
  • Cyclid
  • Emadrin
  • Kemadrin
  • Osnervan
  • Picidin
  • Proimer
  • Youngproma

Procyclidine Brands in Pakistan:

Procyclidine (Hcl) [Inj 10 M/2ml]

Zyclidine Mass Pharma (Private) Limited

 

Procyclidine (Hcl) [Inj 10 Mg/2ml]

Epsent Genetics Pharmaceuticals
Xprodine Mass Pharma (Private) Limited

 

Procyclidine (Hcl) [Tabs 5 Mg]

Cyclidine Pharmedic (Pvt) Ltd.
Kemadrin Glaxosmithkline
Kempro Adamjee Pharmaceuticals (Pvt) Ltd.
Procholidin Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Procye Glitz Pharma
Prosyclidine Werrick Pharmaceuticals

 

Procyclidine (Hcl) [Tabs 50 Mg]

Zyclofenac-P Zephyr Pharmatec (Pvt) Ltd.